EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access

Genomic Characterization and Prognostic Significance of Human Epidermal Growth Factor Receptor 2–Low, Hormone Receptor–Positive, Early Breast Cancers From the BIG 1-98 and SOFT Clinical Trials

Stephen J Luen, Lauren C Brown, Courtney T van Geelen iD, Peter Savas iD, Roswitha Kammler iD, Patrizia Dell'Orto iD, Olivia Biasi, Alan S Coates iD, Richard D Gelber iD, Beat Thürlimann, Marco Colleoni iD, Gini F Fleming iD und 4 weitere

JCO Precision Oncology · 2025

DOI: 10.1200/po-24-00599 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift JCO Precision Oncology, 2025. Verfasst von Stephen J Luen und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Receptors, Estrogen, Receptors, Progesterone. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE To investigate whether hormone receptor–positive, human epidermal growth factor receptor 2–low (HR+HER2-low) versus HR+HER2-zero early breast cancers have distinct genomic and clinical characteristics. METHODS This study included HR+, HER2-negative early breast cancers from patients enrolled in the phase III, randomized BIG 1-98 and SOFT clinical trials that had undergone tumor genomic sequencing. Tumors were classified HR+HER2-low if they had a centrally reviewed HER2 immunohistochemistry (IHC) score of 1+ or 2+ with negative in situ hybridization and HR+HER2-zero if they had an HER2 IHC score of 0. RESULTS A total of 1,795 tumors were evaluable for this study (BIG 1-98 n = 520, SOFT n = 1,275). The frequency of HER2-low tumors was 37% and 21% in the postmenopausal BIG 1-98 and premenopausal SOFT cohorts, respectively. There were no significant differences in clinicopathologic variables between HER2-low and HER2-zero groups which was consistent across both trials. There was no significant difference in risk of distant recurrence for patients with HER2-low tumors versus HER2-zero tumors (5-year % distant recurrence-free 94.0% v 92.8%, P = .61, in BIG 1-98; 89.4% v 92.7%, P = .31, in SOFT, respectively). Somatic genomic profiles were similar with the exception of MAP3K1 mutations which were more frequent in HER2-zero tumors (BIG 1-98 19% v 5%, SOFT 11% v 6%). Both ERBB2 copy number and ERBB2 gene expression abundance were significantly higher in HER2-low tumors compared with HER2-zero tumors; however, the absolute difference was small. Correlation between ERBB2 copy number values and gene expression was modest ( r = 0.17). CONCLUSION In two large clinical trials with centrally reviewed HER2 IHC, our findings do not support HER2-low breast cancer as a distinct clinical or biologic entity among HR+HER2- early breast cancers. Absolute differences in median ERBB2 copy number levels or gene expression are small and of unclear biologic relevance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, ProgesteroneHumansFemalePrognosisMiddle AgedGenomicsAdultAged

Substanzen

Erb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, ProgesteroneERBB2 protein, human

Autor:innen und Institutionen

  • Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Sir Peter MacCallum Department of Oncology, The University of Melbourne, Victoria, Australia.
  • International Breast Cancer Study Group, Coordinating Center, Central Pathology Office, Bern, Switzerland.
  • International Breast Cancer Study Group Central Pathology Office, Milan, Italy.
  • Department of Pathology and Laboratory Medicine, IEO European Institute of Oncology IRCCS, Milan, Italy.
  • International Breast Cancer Study Group and University of Sydney, Sydney, Australia.

ORCID-Profile: Courtney T van Geelen, Peter Savas, Roswitha Kammler, Patrizia Dell'Orto, Alan S Coates, Richard D Gelber, Marco Colleoni, Gini F Fleming, Prudence A Francis, Meredith M Regan, Giuseppe Viale, Sherene Loi

Förderung

  • NCI NIH HHS

Zitieren

APA

Luen, S. J., Brown, L. C., van Geelen, C. T., Savas, P., Kammler, R., Dell'Orto, P., Biasi, O., Coates, A. S., Gelber, R. D., Thürlimann, B., Colleoni, M., Fleming, G. F., Francis, P. A., Regan, M. M., Viale, G., & Loi, S. (2025). Genomic Characterization and Prognostic Significance of Human Epidermal Growth Factor Receptor 2–Low, Hormone Receptor–Positive, Early Breast Cancers From the BIG 1-98 and SOFT Clinical Trials. JCO Precision Oncology. https://doi.org/10.1200/po-24-00599

Vancouver

Luen SJ, Brown LC, van Geelen CT, Savas P, Kammler R, Dell'Orto P, et al. Genomic Characterization and Prognostic Significance of Human Epidermal Growth Factor Receptor 2–Low, Hormone Receptor–Positive, Early Breast Cancers From the BIG 1-98 and SOFT Clinical Trials. JCO Precision Oncology. 2025. doi:10.1200/po-24-00599

BibTeX
@article{Luen2025,
  author = {Luen, Stephen J and Brown, Lauren C and van Geelen, Courtney T and Savas, Peter and Kammler, Roswitha and Dell'Orto, Patrizia and Biasi, Olivia and Coates, Alan S and Gelber, Richard D and Thürlimann, Beat and Colleoni, Marco and Fleming, Gini F and Francis, Prudence A and Regan, Meredith M and Viale, Giuseppe and Loi, Sherene},
  title = {Genomic Characterization and Prognostic Significance of Human Epidermal Growth Factor Receptor 2–Low, Hormone Receptor–Positive, Early Breast Cancers From the BIG 1-98 and SOFT Clinical Trials},
  journal = {JCO Precision Oncology},
  year = {2025},
  doi = {10.1200/po-24-00599}
}
Kostenlos starten →